KYORIN Holdings, Inc. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2019; Provides Consolidated Earnings Guidance for the Fiscal Year 2020 Ending March 31, 2020; Announces Dividend for the Second Quarter Ended September 30, 2019, Payable on December 3, 2019; Provides Dividend Forecast for the Fiscal Year Ending March 31, 2020
November 07, 2019
Share
KYORIN Holdings, Inc. reported consolidated earnings results for the Six Months Ended September 30, 2019. For the quarter, the company reported net sales of JPY 48,299 million against JPY 50,360 million a year ago. Operating income was JPY 783 million against JPY 2,852 million a year ago. Profit attributable to owners of parent was JPY 834 million against JPY 2,217 million a year ago. Net income per share was JPY 14.56 against JPY 30.04 a year ago.
For the year ending March 31, 2020, the company expects consolidated net sales of JPY 109,400 million, operating income of JPY 6,500 million, and profit attributable to owners of parent of JPY 5,400 million or JPY 94.26 per share.
The company announced dividend for the second quarter ended September 30, 2019. For the second quarter, the company announced dividend of JPY 30.00 against JPY 30.00 in the same period a year ago. The scheduled date for starting dividend payment is December 3, 2019.
The company provides dividend forecast for the fiscal year ending March 31, 2020. For the fiscal year, the company expects to pay dividend of JPY 45.00 per share against JPY 45.00 per share a year ago.
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.
KYORIN Holdings, Inc. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2019; Provides Consolidated Earnings Guidance for the Fiscal Year 2020 Ending March 31, 2020; Announces Dividend for the Second Quarter Ended September 30, 2019, Payable on December 3, 2019; Provides Dividend Forecast for the Fiscal Year Ending March 31, 2020
KYORIN PHARMACEUTICAL CO., LTD. 
